Biogen
NEWS
Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis. Samsung Bioepis focuses on developing biosimilar drugs and is a joint venture between Samsung Biologics and Biogen formed in 2012.
Researchers at the University of California, San Diego (UCSD) ran successful animal studies of a gene therapy that appeared to cure a disease in mice similar to amyotrophic lateral sclerosis (ALS), sometimes also known as Lou Gehrig’s Disease.
It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016.
After releasing positive topline data from the Phase II study of BAN2401 as a potential treatment for Alzheimer’s disease in July, some of the numbers did not hold up. This morning Biogen and its developmental partner Eisai attempted to provide an update on the information to show that the anti-amyloid plaque treatment still has some life.
However, because the trial did show some efficacy and met other secondary endpoints, the companies are continuing to analyze the data and decide on their next moves.
Multiple biotech companies are scheduled to release their quarterly reports next week. BioSpace takes a quick look at some these companies and the announcements they have made through 3Q2018.
Every year, the Breakthrough Prize Foundation awards a collective total of $22 million to nine researchers for achievements in the Life Sciences, Fundamental Physics and Mathematics.
Again and again … and again, drugs have failed in clinical trials for Alzheimer’s disease. According to a new report, in the last decade, 146 drugs have failed in clinical trials for Alzheimer’s.
Forbes came out with its ranking of the World’s Best Employers 2018, with a number of global biopharmaceutical companies ranked high on the list. Here’s the top 10 in that category.
JOBS
IN THE PRESS